Company Description
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally.
Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens.
In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease.
T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2006 |
| IPO Date | Aug 7, 2014 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 113 |
| CEO | John Sperzel |
Contact Details
Address: 101 Hartwell Avenue Lexington, Massachusetts 02421 United States | |
| Phone | 781 761 4646 |
| Website | t2biosystems.com |
Stock Details
| Ticker Symbol | TTOO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001492674 |
| CUSIP Number | 89853L104 |
| ISIN Number | US89853L3024 |
| Employer ID | 20-4827488 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| John J. Sperzel III, B.Sc. | President, Chief Executive Officer and Chairman |
| John M. Sprague CPA | Chief Financial Officer |
| Michael Terrence Gibbs Esq. | Senior Vice President, General Counsel and Company Secretary |
| Kelley J. Morgan | Chief People Officer |
| Brett A. Giffin | Chief Commercial Officer |
| Dr. Roger Smith Ph.D. | Senior Vice President of Science Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 8-K | Current Report |
| Nov 20, 2024 | ARS | Filing |
| Nov 20, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |